RAPID

Terminated

Retrieval of Patient Information After Discontinuation

A Phase 3b Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies ELN15727-301 and 302 But Did Not Enroll in Study ELN115727-351

Lead sponsor

JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Asset

Bapineuzumab

Listed sites

Recruiting sites

Enrollment

169

actual

Study population

Alzheimer’s disease

Key I/E criterion

•Study partner/caregiver required

Primary endpoint

•Dependence Scale

Identifiers

Registered as

Org study IDAAB-001-ALZ-3300

NCT IDNCT01658722

Timeline

Milestones

Study start2011-12 (month precision)

Primary completion2012-08actual (month precision)

Study completion2012-08actual (month precision)

Study first posted2012-08-07estimated

Last update posted2015-09-02estimated

Assets

Drug assets

Bapineuzumab

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age55 Years

SexAll

Healthy volunteersNot accepted

Eligibility criteria

1. Signed, dated, and written informed consent obtained from the subject and/or the subject's legally acceptable representative (LAR, if applicable) in accordance with local regulations.

2. Signed, dated, and written informed consent, obtained from the subject's caregiver in accordance with local regulations.

3. Subject must have participated in the Study 301, 302, or 351 and have received at least 1 dose of study treatment (bapineuzumab or placebo).

4. Subject must have been off treatment for at least 12 months prior to Visit 1.

5. Subjects must have a primary caregiver for the duration of the study.

6. Subject's caregiver must have the ability to assess the subject and answer questions over the phone.

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Caregiver / quality of life

1 endpoint

Primary/protocol endpoint

Dependence Scale

Time frame:4 years

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.